An interventional study of Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg in HIV Infections, sponsored by Centers for Disease Control and Prevention. Completed. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-13.
Sponsored by Centers for Disease Control and Prevention · Not applicable, Interventional, and Prevention
This study is an open label and is an extension to the TDF2 study in which the investigators offered daily oral tenofovir/emtricitabine (TDF/FTC) for a maximum of 12 months to HIV uninfected former participants of the TDF2 study.
This open label phase builds on a unique opportunity provided by the end of the randomized phase of the TDF 2 study. The randomized study provided a well-characterized cohort of persons who received standard prevention interventions, including monthly testing, counseling, and condoms. The primary intervention that will change in the open label phase is the provision of information about the demonstrated efficacy and safety of PrEP including counseling about how PrEP is not 100% effective, provision of open label rather than blinded study medication, and a shortened visit schedule designed to more closely approximate what would be feasible in an implementation program. This open label phase will therefore serve as an opportunity to gather additional information relevant to the delivery and uptake of daily oral PrEP that may help inform eventual more wide scale PrEP implementation in Botswana.The OLE also leverages unique opportunities to address important questions about how information about PrEP safety and efficacy might affect risk behavior. The randomized trial showed that condom use (81.9% in the TDF/FTC group and 79.7% in the placebo group, p = 0.21) and the number of participants with more than one sexual partner in the previous month (14.2% in the TDF/FTC group and 14.1% in the placebo group, p = 0.86) between the two groups was similar. The underlying premise of this OLE is that information about PrEP efficacy and the knowledge of taking active drug rather than placebo might alter perception of HIV risk. This extension seeks to determine whether this trend will occur in the cohort after individuals receive information and counseling about the partial protective efficacy of PrEP and to identify risk factors for changes in risk behavior. The randomized trial revealed that reported drug adherence between the two arms was almost identical at 84.1% in the TDF/FTC group and 83.7% in the placebo arm (p = 0.79). The investigators have designed this open label phase in order to determine 1) if the knowledge of receiving active drug and the receipt of information about PrEP safety and partial efficacy at the onset of the open label phase could have substantial effects on pill use and 2) to identify individual factors associated with this impact. In addition, the open label extension will provide more information about the long term safety of Truvada.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 229 is above the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →Centers for Disease Control and Prevention is the lead sponsor of 273 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
Drug: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Also known as: Truvada
Self-reported Drug Adherence Over the Past 3 Days
A 30-day supply of TDF/FTC was dispensed at each monthly visit, for up to 12 months. Participants were asked monthly about their drug adherence and were asked to recall their time of dosing over the past 3 days. Question: "Please think back to \[yesterday, 2 days ago, 3 days ago\]. What time did you take Truvada? Was it in the morning, afternoon, evening, or you weren't able to take the pill that day?"
Time frame: Up to 12 Months
Number of Sex Partners
Number of sex partners was assessed at baseline and each scheduled monthly visit, for up to 12 months. Responses to the following question refers to the number of partners reported in the past 30 days: "In the past 30 days, with how many partners have you had sexual intercourse?"
Time frame: Up to 12 months
Number of Sex Acts by Condom Usage
Number of sex acts by condom usage was assessed at baseline and each scheduled monthly visit, for up to 12 months. Responses to the following question refers to the number of sex acts with up to 3 partners. "In the past 30 days, how many times did you have sex with \['this partner'\]? When I ask about the number of times you had sex, please count each sexual act. For example, if you had 2 rounds of sexual intercourse with your partner on a single evening, count that as two times you had sex. Please remember that this only refers to vaginal and anal sex. It does not refer to oral sex." To assess condom use by sex act, the following question was asked to assess the number of sex acts with condoms and without condoms with up to 3 partners: "Of the ___ sex acts, how many times did you not use condoms the entire time?"
Time frame: Up to 12 months
Extracellular Tenofovir (TFV) for Recent Drug Exposure
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring extracellular tenofovir (TFV) for recent drug exposure (\~24 hours). Of 229 participants, 196 participants had monthly DBSs available for analysis. A sampling algorithm was designed to make inference to TFV and TFV-DP levels at all 12 months. For the TFV extracellular analysis, participants were randomly assigned to one of three sampling schedules, with equal probability: (a) months 1, 2, 5, 8, and 11; (b) months 1, 3, 6, 9, and 12; and (c) months 1, 4, 7, 10, and 12. These 196 participants contributed a total of 777 monthly DBSs for the TFV extracellular analysis. Extracellular TFV detectability was defined as having a mean TFV level (of up to four measurements) equal to or greater than 5 ng/mL.
Time frame: Up to 12 months
Intracellular Tenofovir-diphosphate (TFV-DP)
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring intracellular tenofovir-diphosphate (TFV-DP) for long-term drug exposure (\~7 days). The 196 participants who had monthly DBSs available were stratified by site, gender, and the 3 patterns previously assigned for the TFV extracellular analysis (2×2×3 = 12 strata). Then 60 participants were selected, 5 from each of the 12 strata, to balance by site, gender, and the above 3 patterns were maintained. In turn, the monthly DBSs indicated by the assigned pattern were analyzed. These 60 participants contributed a total of 237 monthly DBSs for the TFV-DP intracellular analysis. The observed TFV-DP levels in our study population were categorized as follows (units of drug in fmol/mL): 0 doses per week (\<912); 1 dose taken per week (≥912 and \<1824); 2 doses taken per week (≥1824 and \<2688); 3 doses taken per week (≥2688 and \<3600); 4 doses taken per week (≥3600 and \<4464); 5 to 7 doses taken
Time frame: Up to 12 months
HIV Seroconversion
Study visits were scheduled every month until completion of the study and during monthly study visits, HIV testing was performed, for up to 12 months. During monthly visits, routine HIV testing was performed with two HIV rapid tests. If HIV-infection was suspected, HIV antigen-antibody (Ag/Ab) combination enzyme immunoassay (EIA) (Bio-Rad, GS HIV Combo Ag/Ab EIA) testing was performed, and RNA viral load was measured.
Time frame: Up to 12 Months
Serious Adverse Events
Study visits were scheduled every month until study completion. Participants were instructed to return to the clinic for evaluation in event of illness. Participants reported any adverse effects (AEs) at monthly or interim visits and were determined as serious adverse events (SAE) when at least possibly related to study drug. DAIDS Table for Grading Severity of Adult Adverse Experiences for Vaccine \& Prevention Research Programs was used for grading. Definitions: Grade 3-'probably related'-strong temporal relationship to study product that cannot be explained by participant's clinical state or other factors and a causal relationship is biologically plausible. Grade 4-'definitely related'-distinct temporal relationship to administration of the study product that cannot be explained by the participant's clinical state or other factors or AE occurs on re-challenge or the AE is a known reaction to the product or chemical group or can be predicted by the product's pharmacology.
Time frame: Up to 12 Months
| Milestone | TDF-FTC as PrEP |
|---|---|
| Started | 229 |
| Completed | 153 |
| Not completed | 76 |
A 30-day supply of TDF/FTC was dispensed at each monthly visit, for up to 12 months. Participants were asked monthly about their drug adherence and were asked to recall their time of dosing over the past 3 days. Question: "Please think back to \[yesterday, 2 days ago, 3 days ago\]. What time did you take Truvada? Was it in the morning, afternoon, evening, or you weren't able to take the pill that day?"
| Participants | TDF-FTC as PrEP |
|---|---|
| Took daily dosage in past 3 days | 199 |
| Took 2 doses in past 3 days | 9 |
| Took 1 doses in past 3 days | 2 |
| No doses taken in past 3 days | 19 |
Number of sex partners was assessed at baseline and each scheduled monthly visit, for up to 12 months. Responses to the following question refers to the number of partners reported in the past 30 days: "In the past 30 days, with how many partners have you had sexual intercourse?"
| sexual partners | TDF-FTC as PrEP |
|---|---|
| Number of sex partners among women, overall | 0.87 ± 0.53 |
| Number of sex partners among men, overall | 1.03 ± 0.74 |
Number of sex acts by condom usage was assessed at baseline and each scheduled monthly visit, for up to 12 months. Responses to the following question refers to the number of sex acts with up to 3 partners. "In the past 30 days, how many times did you have sex with \['this partner'\]? When I ask about the number of times you had sex, please count each sexual act. For example, if you had 2 rounds of sexual intercourse with your partner on a single evening, count that as two times you had sex. Please remember that this only refers to vaginal and anal sex. It does not refer to oral sex." To assess condom use by sex act, the following question was asked to assess the number of sex acts with condoms and without condoms with up to 3 partners: "Of the ___ sex acts, how many times did you not use condoms the entire time?"
| sex acts | TDF-FTC as PrEP |
|---|---|
| Number of sex acts among women | 4.01 ± 5.26 |
| Number of sex acts among men | 5.95 ± 6.67 |
| Number of condomless sex acts among women | 1.28 ± 3.72 |
| Number of condomless sex acts among men | 1.70 ± 4.34 |
| Number of sex acts involving a condom among women | 2.72 ± 3.70 |
| Number of sex acts involving a condom among men | 4.24 ± 5.19 |
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring extracellular tenofovir (TFV) for recent drug exposure (\~24 hours). Of 229 participants, 196 participants had monthly DBSs available for analysis. A sampling algorithm was designed to make inference to TFV and TFV-DP levels at all 12 months. For the TFV extracellular analysis, participants were randomly assigned to one of three sampling schedules, with equal probability: (a) months 1, 2, 5, 8, and 11; (b) months 1, 3, 6, 9, and 12; and (c) months 1, 4, 7, 10, and 12. These 196 participants contributed a total of 777 monthly DBSs for the TFV extracellular analysis. Extracellular TFV detectability was defined as having a mean TFV level (of up to four measurements) equal to or greater than 5 ng/mL.
| number of DBS samples | TDF-FTC as PrEP |
|---|---|
| Detectable TFV | 713 |
| No detectable TFV | 64 |
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring intracellular tenofovir-diphosphate (TFV-DP) for long-term drug exposure (\~7 days). The 196 participants who had monthly DBSs available were stratified by site, gender, and the 3 patterns previously assigned for the TFV extracellular analysis (2×2×3 = 12 strata). Then 60 participants were selected, 5 from each of the 12 strata, to balance by site, gender, and the above 3 patterns were maintained. In turn, the monthly DBSs indicated by the assigned pattern were analyzed. These 60 participants contributed a total of 237 monthly DBSs for the TFV-DP intracellular analysis. The observed TFV-DP levels in our study population were categorized as follows (units of drug in fmol/mL): 0 doses per week (\<912); 1 dose taken per week (≥912 and \<1824); 2 doses taken per week (≥1824 and \<2688); 3 doses taken per week (≥2688 and \<3600); 4 doses taken per week (≥3600 and \<4464); 5 to 7 doses taken
| number of DBS samples | TDF-FTC as PrEP |
|---|---|
| 7 doses per week | 141 |
| 6 doses per week | 29 |
| 5 doses per week | 20 |
| 4 doses per week | 6 |
| 3 doses per week | 12 |
| 2 doses per week | 4 |
| 1 dose per week | 5 |
| 0 doses per week | 19 |
Study visits were scheduled every month until completion of the study and during monthly study visits, HIV testing was performed, for up to 12 months. During monthly visits, routine HIV testing was performed with two HIV rapid tests. If HIV-infection was suspected, HIV antigen-antibody (Ag/Ab) combination enzyme immunoassay (EIA) (Bio-Rad, GS HIV Combo Ag/Ab EIA) testing was performed, and RNA viral load was measured.
| Participants | TDF-FTC as PrEP |
|---|---|
| HIV Seroconversion | 0 |
Study visits were scheduled every month until study completion. Participants were instructed to return to the clinic for evaluation in event of illness. Participants reported any adverse effects (AEs) at monthly or interim visits and were determined as serious adverse events (SAE) when at least possibly related to study drug. DAIDS Table for Grading Severity of Adult Adverse Experiences for Vaccine \& Prevention Research Programs was used for grading. Definitions: Grade 3-'probably related'-strong temporal relationship to study product that cannot be explained by participant's clinical state or other factors and a causal relationship is biologically plausible. Grade 4-'definitely related'-distinct temporal relationship to administration of the study product that cannot be explained by the participant's clinical state or other factors or AE occurs on re-challenge or the AE is a known reaction to the product or chemical group or can be predicted by the product's pharmacology.
| participants | TDF-FTC as PrEP |
|---|---|
| Hyperamylasemia, Grade 3 | 2 |
| Hypophosphatemia, Grade 3 | 5 |
| Hypercreatininemia, Grade 1 | 1 |
Collected over Adverse event data was collected over the period of 12 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TDF-FTC as PrEP | — | 8/229 (3.5%) | 169/229 (73.8%) |
| Event | TDF-FTC as PrEP |
|---|---|
| HypophosphatemiaBlood and lymphatic system disorders | 5/229 |
| HyperamylasemiaBlood and lymphatic system disorders | 2/229 |
| Elevated creatinineRenal and urinary disorders | 1/229 |
| Event | TDF-FTC as PrEP |
|---|---|
| HyperamylasemiaBlood and lymphatic system disorders | 126/229 |
| HypophosphatemiaBlood and lymphatic system disorders | 58/229 |
| TransaminitisGastrointestinal disorders | 22/229 |
| HeadacheGeneral disorders | 21/229 |
| HyperbilirubinemiaBlood and lymphatic system disorders | 17/229 |
| DizzinessNervous system disorders | 17/229 |
| HypocalcemiaBlood and lymphatic system disorders | 15/229 |
| NauseaGastrointestinal disorders | 14/229 |
| VomitingGastrointestinal disorders | 13/229 |
| Pain, abdominalGastrointestinal disorders | 11/229 |
| Age, Categorical(Participants) | TDF-FTC as PrEP |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 229 |
| >=65 years | 0 |
| Age, Continuous(years) | TDF-FTC as PrEP |
|---|---|
| Median | 30 (28 to 33) |
| Sex: Female, Male(Participants) | TDF-FTC as PrEP |
|---|---|
| Female | 102 |
| Male | 127 |
| Race/Ethnicity, Customized(Participants) | TDF-FTC as PrEP |
|---|---|
| Black | 229 |
| Region of Enrollment(participants) | TDF-FTC as PrEP |
|---|---|
| Botswana | 229 |
| Enrollment Site(Participants) | TDF-FTC as PrEP |
|---|---|
| Gaborone | 132 |
| Francistown | 97 |
| Education Level(Participants) | TDF-FTC as PrEP |
|---|---|
| Primary or less | 4 |
| Secondary | 141 |
| Post-secondary | 84 |
| Marital Status(Participants) | TDF-FTC as PrEP |
|---|---|
| Single | 163 |
| Married | 18 |
| Cohabitating | 37 |
| Separated/Widowed | 11 |
4 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No — Data cannot be shared publicly without permission from the country of Botswana but may be available upon request.
No publications or documents are linked to this record.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centers for Disease Control and Prevention